Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza virus vaccine (Optaflu, Flucelvax, Flucelvax TETRA ) - Seqirus

Drug Profile

Influenza virus vaccine (Optaflu, Flucelvax, Flucelvax TETRA ) - Seqirus

Alternative Names: FLUCELVAX; Flucelvax; Flucelvax Pediatric; Flucelvax Quadrivalent; Flucelvax TETRA; Influenza vaccine (Flucelvax); Influenza vaccine (prepared in cell culture) - Seqirus; Optaflu; QIVc; TIVc

Latest Information Update: 04 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Seqirus
  • Class Influenza virus vaccines; Subunit vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 06 Sep 2019 Phase-III clinical trials in Influenza virus infections (In children, In infants, Prevention) in USA (IM) (NCT04074928)
  • 05 Sep 2019 Seqirus plans a phase III trial in Influenza virus infections (Prevention, In infants)
  • 20 Aug 2019 Seqirus plans to launch FLUCELVAX® in Australia in H2 2021 (CSL Behring pipeline, April 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top